Gilead's selonsertib fails PhIII in less sick NASH patients — to no one's surprise
The prospects of Gilead’s top late-stage NASH drug selonsertib grew dim when it kicked off Phase III readouts with a flop. Two months later, the company conceded that a second, much similar trial has also failed.
STELLAR-3 set out to measure how well selonsertib, an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), can improve fibrosis without NASH worsening. That’s the same primary endpoint as STELLAR-4, except that STELLAR-3 recruited patients at a slightly earlier stage of disease — with F3, or bridging, fibrosis — compared to the cirrhosis (F4 fibrosis) patients enrolled in the other trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.